Sunshine Biopharma, Inc. (SBFM) AI Stock Analysis

Sunshine Biopharma, Inc. is a pharmaceutical and nutritional supplement company based in Pointe-Claire, Canada. It specializes in researching and developing anticancer drugs and science-based nutritional supplements. The company's lead anticancer drug candidate is Adva-27a, designed to target cancers such as leukemia, lymphoma, lung, prostate, ovarian, and liver cancers, as well as multidrug-resistant cancer cells. Sunshine Biopharma is also developing SBFM-PL4, an anti-coronavirus treatment compound under a license agreement with the University of Georgia. In addition, the company markets over-the-counter supplements, including Essential 9 and Essential Calcium-Vitamin D tablets.

Sunshine Biopharma expanded annual revenue from $228,426 in FY2021 to $4.3M in FY2022 and $24.1M in FY2023. Revenue reached $34.9M in FY2024 and grew 4.1% to $36.3M in FY2025, reflecting a 5-year revenue CAGR of 247.7% from FY2020 to FY2025. Gross margin stood at 32.8% in FY2025, compared to 30.6% in FY2024 and 48.4% in FY2021. However, operating margin remained negative at -12.3% in FY2025, with net income of -$6.0M. For the latest quarter ended June 30, 2026, quarterly revenue fell 1.6% year-over-year, while trailing twelve-month revenue reached $35.3M with an operating margin of -17.4%.

As of June 30, 2026, Sunshine Biopharma held $13.7M in cash and short-term investments against total debt of $678,338, resulting in net cash of $13.1M. The company's current ratio stood at 5.46 and debt-to-equity was 0.02. Total assets were $33.6M, supported by shareholders' equity of $27.5M. Operating cash flow was -$5.3M in FY2025, and free cash flow was -$5.5M after capital expenditures of $174,487. Over five years, the company's share count increased 280.8%.

At a share price of $0.22 as of October 16, 2026, Sunshine Biopharma has a market cap of $3.3M and an enterprise value of -$9.5M. The stock trades at a price-to-sales multiple of 0.1x and a price-to-book ratio of 0.1x, which compares to a median price-to-sales multiple of 4.1x for its US-listed Healthcare peers. Over the past year, SBFM shares fell 99.0%, underperforming the S&P 500 (SPY) return of 16.8%. The stock also trades 96.4% below its 200-day moving average.

Sunshine Biopharma has 1 Strong Buy rating, 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings from analysts. The mean price target is $56.00, representing a 25125.2% premium over the last close of $0.22. For the current fiscal year ending December 31, 2026, the analyst revenue estimate is $36.8M with an EPS estimate of -$1.95. For next fiscal year, projected revenue is $45.0M. Sunshine Biopharma posted 1 EPS beat over the last 4 quarters, and its next earnings date is November 12, 2026.

This page is an AI-written research summary of Sunshine Biopharma, Inc. (SBFM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SBFM income statement, SBFM balance sheet, SBFM key metrics, SBFM analyst forecast, SBFM chart. See the SBFM stock overview for the latest quote and news.